Picture of Akoya Biosciences logo

AKYA — Akoya Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Akoya Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview

* Akoya Biosciences Inc  AKYA.OQ   AKYA.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 8. 
    * The Marlborough Massachusetts-based  company is expected
to
report  a 20.3% increase in revenue to $20.32 million from
$16.89 million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Akoya Biosciences
Inc is
for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Akoya
Biosciences
Inc is $17.5​, above​ its last closing price of $6.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.44       -0.43      -0.50     Missed  -16.3
 Sep. 30 2022  -0.49       -0.44      -0.47     Missed  -6.8
 Jun. 30 2022  -0.39       -0.37      -0.47     Missed  -26.3​
 Mar. 31 2022  -0.40       -0.39      -0.44     Missed  -13.5
 ​​Dec.        -0.29       -0.31      -0.47     Missed  -51.6
 31 2021                                                
 Sep. 30 2021  -0.26       -0.26      -0.31     Missed  -17​
 Jun. 30 2021  -0.23       -0.23      -0.20     Beat    13
 Mar. 31 2021  -0.17       -0.17      -3.54     Missed  -2,013
                                                        .4
 This summary was machine generated May 6 at 02:09 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Akoya Biosciences

See all news